Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Seattle Genetics and Collaborators Highlight Multiple Ab-Drug Conjugate (ADC)

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Presentations highlight preclinical data for novel programs and breakthroughs in research to develop highly stable linkers and more potent chemotypes.

Seattle Genetics, Inc. announced that research related to its antibody-drug conjugate (ADC) technology was presented in multiple sessions at the 104th Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C. Three data presentations highlight the rapid progress being made in ADC technology and testing. This includes preclinical data evaluating ADCs using a potent and newly developed cytotoxic agent, pyrrolobenzodiazepine (PBD) dimer, against two targets, CD33 and CD70. The former, SGN-CD33A, is expected to be advanced into a phase 1 clinical trial in 2013 for patients with acute myeloid leukemia (AML). In addition, preclinical data demonstrate activity of a new ADC for metastatic breast cancer, SGN-LIV1A, utilizing the same proprietary ADC technology as ADCETRIS® (brentuximab vedotin). The company also presented research on a novel method for making highly stable linkers, an advance that is being evaluated for potential future ADCs. In addition, many of the company’s collaborators, including Genentech, Pfizer, Progenics and Genmab, are reporting preclinical and clinical data from multiple ADC programs utilizing Seattle Genetics’ proprietary ADC technology.

“As the leader in developing ADCs for the treatment of cancer, we are focused on both the current and future technology of this important class of therapeutics. More than half of the ADCs currently in clinical development utilize our technology, and we continue to advance additional candidates, such as SGN-CD33A and SGN-LIV1A, at a rapid pace. We are also looking at ways to enhance the next generation of ADCs, and believe that new potent cytotoxic agents such as PBD dimers, advances in antibody technology such as engineered cysteine antibodies (EC-mAbs), and highly stable linkers are part of that future,” said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. “We are driven to test these ADC advances quickly because cancer patients need new options to fight this relentless disease.”

ADCs are designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. Seattle Genetics and its collaborators have ten data presentations at AACR that highlight the widespread evaluation of its ADC technology to potentially impact the way cancer is treated in a meaningful way.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Seattle Genetics and Genmab Collaborate
Collaboration combines Genmab’s proprietary antibodies and Seattle Genetics’ ADC technology. The new ADC program will target AXL expressed on multiple tumor types.
Friday, September 12, 2014
Seattle Genetics and Genmab Enter into New ADC Collaboration
New ADC program will target AXL expressed on multiple tumor types.
Thursday, September 11, 2014
Seattle Genetics and Agensys Announce Co-Development of Antibody-Drug Conjugate
Seattle Genetics has exercised an option to co-develop an additional ADC under the companies’ existing ADC collaboration agreement.
Monday, July 01, 2013
Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer
Seattle Genetics eligible to potentially receive more than $500 million in fees and milestones plus royalties under multi-target deal.
Wednesday, June 26, 2013
Seattle Genetics Reports First Quarter 2013 Financial Results
Total revenues of $57.3 million, including $33.9 million in ADCETRIS® (Brentuximab Vedotin) net product sales.
Thursday, May 09, 2013
Seattle Genetics and Oxford BioTherapeutics to Collaborate on ADCs for Cancer
Companies to combine proprietary technologies to generate novel ADC product candidates.
Friday, November 04, 2011
Seattle Genetics Initiates Brentuximab Vedotin Retreatment Clinical Trial
Trial will evaluate tolerability and activity when retreating patients who relapse after previously achieving an objective response to brentuximab vedotin.
Monday, July 27, 2009
Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
SGN-35 is an ADC that utilizes proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Friday, June 19, 2009
Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data
Company reports multiple objective responses at well-tolerated doses from a phase I clinical trial of SGN-33 in patients with AML.
Wednesday, June 10, 2009
Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
Company to present during a Clinical Science Symposium at ASCO Annual Meeting being held in Orlando, Florida.
Tuesday, June 02, 2009
Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma
Reported demonstrate enhanced activity of dacetuzumab combined with Rituxan in patients with relapsed or refractory Hodgkin lymphoma.
Monday, December 08, 2008
Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial
SGN-35 is an antibody-drug conjugate that utilizes company’s technology to empower antibodies by linking them to potent cell-killing drugs.
Monday, March 31, 2008
Seattle Genetics and Agensys Announce Collaboration to Develop ADC Therapies
Both the companies will jointly screen ADC products to an initial target, co-fund all preclinical and clinical development.
Tuesday, January 09, 2007
Seattle Genetics to Present on ADC Technology
The presentations demonstrate the key advances to empower the next generation of targeted cancer therapies.
Tuesday, November 15, 2005
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!